13 January 2017

During the New Years 2017 event of the Radboud university medical center, Jolanda de Vries was honored by Leon van Halder, chairmen of our executive board, with the “Radboud Medal″.

The Radboud Medal is the highest honor awarded annually to a person who has contributed significantly to the objective of the Radboudumc as top knowledge center for academic medicine and health.”

Jolanda de Vries, professor of translational tumor immunology, is working at the Dept. of Tumor Immunology. She established a clinical vaccination program in which tumor-associated antigens loaded on DCs are used to treat both melanoma and colon cancer patients. Major current projects are to translate the DC vaccination into various clinical settings. Recently she and her team obtained a budget of 20 million euros from the national basic health insurance to introducte the experimental treatment with a vaccine that reduced the risk of the recurrence of skin cancer. The treatment will be offered in Nijmegen, Amsterdam, Rotterdam and Zwolle and is led by Jolanda de Vries.

She was awarded this highest honor of our Radboudumc for her great individual merits as a trainer of physicians and researchers, excellent research and her broad commitment to the Radboudumc in general. 

Related news items

ZonMw Open Competition Grant for Annemiek van Spriel and Piet Gros

15 June 2021 Annemiek van Spriel, theme cancer development and immune defense, together with Piet Gros, Dept. of Chemistry, Utrecht University obtained a ZonMw Open Competition Grant to investigate IL-6 receptor structure and signalling in tumor cells. read more

HFSP Grant for Johannes Textor

30 March 2020 Johannes Textor, theme Cancer development and immune defense, has been awarded a program grant of 1 million US dollars by The Human Frontier Science Program (HFSP) to investigate how T cells navigate extremely dense environments using experiments, modeling and methods from pedestrian dynamics. read more

Human pDCs attract cytolytic lymphocytes in anti-cancer vaccination

6 February 2020 RIMLS researchers Jasper van Beek and Jolanda de Vries, theme Cancer development and immune defense, discovered that pDCs can efficiently recruit cytolytic immune effector cells, a property that could be exploited in anti-cancer vaccines. They have published these findings in Cell Reports. read more

ZonMw funding for teams of Michiel Vermeulen and Jolanda de Vries

4 February 2020 The awarded research projects of RIMLS researchers Michiel Vermeulen, Jolanda de Vries, Gerty Schreibelt and Martijn Verdoes and colleagues will initiate new research lines and collaborations between various research groups. read more

Niels Stensen Fellowship for Jorieke Weiden

6 January 2020 Jorieke Weiden was recently awarded a grant from the Niels Stensen Fellowship. Since the 1960s, the Niels Stensen Fellowship has been awarded annually to outstanding researchers who recently received their PhD to enable them to gain research experience at a top university or institute abroad. read more

Galectin-9 controls plasma membrane integrity of dendritic cells

16 December 2019 Laia Querol Cano, theme Cancer development and immune defense, has discovered how galectin-9, a sugar-binding membrane organiser, governs dendritic cell function by intracellularly modulating actin cytoskeleton. These findings are published in the latest issue of iScience. read more